Artivion 2025 Q3 Earnings Strong Performance as Net Income Surges 384.2%

Artivion (AORT) delivered robust Q3 2025 results, surpassing Wall Street estimates with a 18.4% revenue increase and a net income turnaround. The company raised full-year revenue and EBITDA guidance, driven by 38% stent grafts growth and 25% On-X product expansion.

Revenue

Total revenue surged to $113.39 million in Q3 2025, a 18.4% year-over-year increase from $95.78 million. This growth was led by a 38% rise in stent grafts sales, with On-X products contributing a 25% increase. Surgical sealants and tissue processing also saw modest gains, while Bioglue and preservation services grew by 2% and 5%, respectively.

Earnings/Net Income

Artivion returned to profitability with EPS of $0.14 in Q3 2025, reversing from a $0.05 loss in the prior year period—a 380% improvement. Net income reached $6.50 million, up from a $2.29 million loss, reflecting a 384.2% swing. The company’s return to profitability highlights a significant operational turnaround.

Post-Earnings Price Action Review

Shares of Artivion declined 3.77% in the latest trading day and fell 1.10% over the past week, contrasting with a 9.47% month-to-date gain. The stock’s post-earnings volatility suggests mixed investor sentiment, though the CEO emphasized confidence in future growth. Management cited strong clinical progress and strategic refinancing as tailwinds, including a $150 million delayed draw term loan and extended debt maturity to 2031.

CEO Commentary

CEO Pat Mackin highlighted “exceptionally strong” Q3 performance, driven by 38% stent grafts growth and 25% On-X expansion. He noted the enrollment of the first patient in the ARTIZEN U.S. trial and favorable AMDS trial data as key milestones. Strategic refinancing efforts, including securing a lower interest rate and accessing additional liquidity, were cited as critical to the company’s long-term stability.

Guidance

Artivion raised 2025 constant currency revenue guidance to 13–14% (prior: 12–14%) and adjusted EBITDA guidance to 24–28% growth (prior: 21–28%). The company targets $88–$91 million in adjusted EBITDA and anticipates EBITDA growth outpacing revenue expansion.

Additional News

1. Strategic Refinancing: Artivion extended debt maturity to 2031, secured a lower interest rate, and accessed a $150 million delayed draw term loan to fund growth initiatives.

2. Cybersecurity Incident: The company disclosed ongoing financial implications from a 2024 cyberattack, including delayed insurance reimbursements and increased operational costs.

3. Operational Expansion: Artivion purchased facilities in Austin, Texas, to support future manufacturing and R&D needs, signaling commitment to scaling its aortic-centric product portfolio.